Home / Pharmaceutical / US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

Published: Feb 2011 | No Of Pages: 42 | Published By: Assessment Group

Product Synopsis

 
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 
 
Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:
 
  • Older patient with retroperitoneal adenopathy and small lung nodules
  • Anemic patient with extremely high LDH levels
  • Patient with multiple comorbidities including heart and lung disease
  • Patient with one kidney and comorbidities
 
This report allows you to:
 
  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends and the factors that influence treatment decisions
  • Gain actionable data for developing and improving market strategies
  • Pinpoint the needs of your target audience to capitalize on opportunities that improve the position of your product
  • Design messages to advance brand performance and impact decisions
  • Focus your resources to maximize the effectiveness of your budget
Executive Summary
 
Chapter 1: Introduction
Table 1. Treatment Options in Renal Cell Cancer
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Renal Cell Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
 
Chapter 3: Treatment of Good to Moderate Prognosis Renal Cell Cancer
Initial treatment regimen chosen following surgery
Figure 3.1
Other therapeutic agents that would be considered appropriate to include in therapy
Figure 3.2
Treatment decision for medication toxicity
Figure 3.3
Second-line therapy treatment
Figure 3.4
Factors influencing treatment
Figure 3.5
Third-line therapy treatment
Figure 3.6
Most important barrier to optimal patient management
Figure 3.7
Confidence in managing this patient
Figure 3.8
 
Chapter 4: Treatment of Patient with Poor Prognosis Renal Cell Cancer
Appropriate treatment regimen
Figure 4.1
Treatment regarding metabolic and laboratory abnormalities
Figure 4.2
Treatment choice for progressive disease
Figure 4.3
 
Chapter 5: Treatment of Patient with Multiple Comorbidities
Management of patient with COPD
Figure 5.1
Choice of systemic therapy agent
Figure 5.2
Tests to monitor to evaluate increased fatigue with pazopanib
Figure 5.3
Next systemic treatment choice for progressive disease
Figure 5.4
 
Chapter 6: Treatment of Patient with Comorbidities: Solitary Kidney
Treatment regimen for patient with solitary kidney
Figure 6.1
Treatment for disease progression
Table 6.2
Factors influencing treatment decision
Figure 6.3
Most important barriers to treatment
Figure 6.4
Confidence in managing this patient
Figure 6.5
 
Chapter 7: Summary
Appendix A: Survey Instrument
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +